Tumour-specific triple-regulated oncolytic herpes virus to target glioma

Oncotarget

Volumn 7, Issue 19, 2016, Pages 28658-28669

  Delwar, Zahid M ^a   Liu, Guoyu ^a   Kuo, Yvonne ^a   Lee, Cleo ^a   Bu, Luke ^a   Rennie, Paul S ^a   Jia, William W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5'UTR; Glioma; MicroRNA; Oncolytic herpes virus; Survivin

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MICRORNA 124; ONCOLYTIC HERPES VIRUS; SURVIVIN; BIRC5 PROTEIN, HUMAN; HERPES SIMPLEX VIRUS, TYPE 1 PROTEIN ICP4; IMMEDIATE EARLY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; ONCOLYTIC VIRUS;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMPLICON; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SPECIFICITY; FEMALE; GENE EXPRESSION; GLIOMA; GLIOMA CELL LINE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN TISSUE; ICP4 GENE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OPEN READING FRAME; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSLATION REGULATION; VIRUS GENE; VIRUS REPLICATION; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG SCREENING; GENETICS; HEK293 CELL LINE; HUMAN ALPHAHERPESVIRUS 1; PHYSIOLOGY; PROCEDURES; PROMOTER REGION; RAT; TUMOR CELL LINE; TUMOR VOLUME; VERO CELL LINE; VIROLOGY;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FIBROBLAST GROWTH FACTOR 2; GLIOMA; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; RATS; TUMOR BURDEN; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84968918979     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8637     Document Type: Article

References (36)

1. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama. 2013; 310:1842-1850.
2. Wen PY, Kesari S. Malignant gliomas in adults. New England Journal of Medicine. 2008; 359:492-507.
3. Zhang X, Zhang W, Cao W-D, Cheng G, Zhang Y-Q. Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). Experimental and therapeutic medicine. 2012; 3:9-14.
4. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer. 2005; 5:965-976.
5. Smith TT, Roth JC, Friedman GK, Gillespie GY. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic virotherapy. 2014; 2014:21.
6. Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Reviews in medical virology. 2011; 21:213-226.
7. Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Human gene therapy. 1999; 10:2741-2755.
8. Chiocca EA. Oncolytic viruses. Nature Reviews Cancer. 2002; 2:938-950.
9. Wong J, Lee C, Zhang K, S Rennie P, Jia W. Targeted oncolytic herpes simplex viruses for aggressive cancers. Current pharmaceutical biotechnology. 2012; 13:1786-1794.
10. Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proceedings of the National Academy of Sciences. 2001; 98:6396-6401.
11. Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu T-C. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer research. 2009; 69:3472-3481.
12. Lee CY, Bu LX, DeBenedetti A, Williams BJ, Rennie PS, Jia WW. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Molecular Therapy. 2010; 18:929-935.
13. Lee CY, Rennie PS, Jia WW. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clinical Cancer Research. 2009; 15:5126-5135.
14. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. International journal of cancer. 2001; 95:92-95.
15. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature medicine. 1997; 3:917-921.
16. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Journal of Clinical Oncology. 2002; 20:1063-1068.
17. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong WM. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer research. 2003; 63:7724-7732.
18. Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC, Wang XL. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer. 2005; 104:2775-2783.
19. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K. Expression of survivin in astrocytic tumors. Cancer. 2003; 97:1077-1083.
20. Xie D, Zeng Y, Wang H, Wen J, Tao Y, Sham J, Guan X. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. British journal of cancer. 2006; 94:108-114.
21. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. The international journal of biochemistry & cell biology. 1999; 31:59-72.
22. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer research. 2008; 68:631-634.
23. Gu X, Jones L, Lowery-Norberg M, Fowler M. Expression of eukaryotic initiation factor 4E in astrocytic tumors. Applied Immunohistochemistry & Molecular Morphology. 2005; 13:178-183.
24. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Current Biology. 2002; 12:735-739.
25. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-[alpha]-PU. 1 pathway. Nature medicine. 2011; 17:64-70.
26. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell cycle. 2008; 7:2485-2492.
27. Godlewski J, Newton H, Chiocca E, Lawler S. MicroRNAs and glioblastoma; the stem cell connection. Cell Death & Differentiation. 2010; 17:221-228.
28. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC medicine. 2008; 6:14.
29. Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PloS one. 2011; 6:e24248.
30. Huang C, Lin S, Chou M, Ho C, Wang L, Lee Y, Chen C, Yang C. Demonstration of different modes of cell death upon herpes simplex virus 1 infection in different types of oral cells. Acta Virol. 2005; 49:7-15.
31. Fukuhara H, Todo T. Oncolytic herpes simplex virus type 1 and host immune responses. Current cancer drug targets. 2007; 7:149-155.
32. Kyriazis AA, Kyriazis AP. Preferential sites of growth of human tumors in nude mice following subcutaneous transplantation. Cancer research. 1980; 40:4509-4511.
33. Belizário JE. Immunodeficient mouse models: an overview. Open Immunol J. 2009; 2:79-85.
34. Zeier Z, Aguilar JS, Lopez CM, Devi-Rao G, Watson ZL, Baker HV, Wagner EK, Bloom DC. A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system. Journal of neurovirology. 2009; 15:411-424.
35. Lee CY, Bu L, Rennie P, Jia WW. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer gene therapy. 2007; 14:652-660.
36. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochemical and biophysical research communications. 2007; 356:286-292.